CN111991535A - Traditional Chinese medicine extract with function of treating Hp-related gastritis and preparation method and application thereof - Google Patents
Traditional Chinese medicine extract with function of treating Hp-related gastritis and preparation method and application thereof Download PDFInfo
- Publication number
- CN111991535A CN111991535A CN202011040023.7A CN202011040023A CN111991535A CN 111991535 A CN111991535 A CN 111991535A CN 202011040023 A CN202011040023 A CN 202011040023A CN 111991535 A CN111991535 A CN 111991535A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- treating
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 116
- 239000000284 extract Substances 0.000 title claims abstract description 53
- 208000007882 Gastritis Diseases 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 20
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 20
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 20
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 20
- 235000010676 Ocimum basilicum Nutrition 0.000 claims abstract description 20
- 240000007926 Ocimum gratissimum Species 0.000 claims abstract description 20
- 235000002594 Solanum nigrum Nutrition 0.000 claims abstract description 20
- 240000002307 Solanum ptychanthum Species 0.000 claims abstract description 20
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 20
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 19
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 19
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 18
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 18
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 18
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 18
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 18
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 18
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 241000949456 Zanthoxylum Species 0.000 claims abstract description 14
- 241000735527 Eupatorium Species 0.000 claims abstract description 13
- 241001529821 Agastache Species 0.000 claims abstract description 9
- 244000169544 Duchesnea indica Species 0.000 claims abstract description 7
- 241001162994 Rugosus Species 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 47
- 241001673966 Magnolia officinalis Species 0.000 claims description 18
- 240000004510 Agastache rugosa Species 0.000 claims description 14
- 238000002791 soaking Methods 0.000 claims description 14
- 244000084767 Potentilla indica Species 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000012676 herbal extract Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 33
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 10
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 230000008029 eradication Effects 0.000 abstract description 8
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 241000721047 Danaus plexippus Species 0.000 abstract description 5
- 241000590002 Helicobacter pylori Species 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 5
- 229940037467 helicobacter pylori Drugs 0.000 abstract description 5
- 238000010792 warming Methods 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 description 24
- 230000006870 function Effects 0.000 description 23
- 210000002784 stomach Anatomy 0.000 description 17
- 210000000952 spleen Anatomy 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 13
- 206010047700 Vomiting Diseases 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000008673 vomiting Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241001127714 Amomum Species 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 241000308663 Eupatorium fortunei Species 0.000 description 6
- 241001078983 Tetradium ruticarpum Species 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 6
- 208000023652 chronic gastritis Diseases 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 235000007650 Aralia spinosa Nutrition 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 244000089698 Zanthoxylum simulans Species 0.000 description 5
- 208000019790 abdominal distention Diseases 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 4
- 239000003899 bactericide agent Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 235000019633 pungent taste Nutrition 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 206010015137 Eructation Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010067171 Regurgitation Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000027687 belching Diseases 0.000 description 2
- 208000006766 bile reflux Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000746375 Andrographis Species 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000012327 Endoscopic diagnosis Methods 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- IPWKIXLWTCNBKN-UHFFFAOYSA-N Madelen Chemical compound CC1=NC=C([N+]([O-])=O)N1CC(O)CCl IPWKIXLWTCNBKN-UHFFFAOYSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960000197 esomeprazole magnesium Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 239000001713 hyssopus officinalis l. herb Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- KWORUUGOSLYAGD-WLHYKHABSA-N magnesium;5-methoxy-2-[(r)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-WLHYKHABSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960002313 ornidazole Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine extract with a function of treating Hp-related gastritis, and a preparation method and application thereof. The traditional Chinese medicine extract is prepared by decocting traditional Chinese medicine raw materials with water, wherein the traditional Chinese medicine raw materials comprise the following components in parts by mass: 5-14 parts of basil; 2-5 parts of fructus evodiae; 5-14 parts of zanthoxylum seeds; 5-14 parts of black nightshade; 8-16 parts of mock strawberry; 8-16 parts of agastache rugosus; 8-16 parts of eupatorium; 8-16 parts of fructus amomi; 15-25 parts of oriental wormwood; 8-16 parts of immature bitter orange; 8-16 parts of mangnolia officinalis and 2-12 parts of honey-fried licorice root. The traditional Chinese medicine extract with the function of treating the Hp-related gastritis provided by the invention has the advantages that the monarch, the minister, the assistant and the guide supplement each other, the whole formula has the effects of warming yang, eliminating turbidity and detoxifying, the traditional Chinese medicine extract is safe and reliable, has no toxic or side effect, can effectively improve the eradication rate of helicobacter pylori, can reduce the side effect of a bactericidal medicine, and promotes the repair of gastric mucosa, and has an obvious effect.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine extract with a function of treating Hp-related gastritis and a preparation method and application thereof.
Background
Helicobacter pylori (Hp) is a spiral gram-negative bacillus, a major causative agent of chronic gastritis, and has close relationship with the occurrence of peptic ulcer and gastric cancer.
At present, the prevalence rate of chronic gastritis based on endoscopic diagnosis in China is close to 90%, wherein the infection rate of Hp is about 52.2%. Hp infection can cause gastric mucosa inflammation change, Hp virulence factors cause abnormal regulation of signal pathways in gastric epithelial cells, gastric mucosa cells are further damaged, and long-term chronic inflammation can cause gastric mucosa ulcer and even malignant evolution of tumors. Thus, the world health organization classifies Hp as a class i carcinogen.
Modern medicine considers that after Hp infection, a radical treatment principle is a key step of treatment, and triple and quadruple bactericidal therapy is mostly adopted. However, with the increase of the Hp infection rate, the above treatment causes drug resistance of the organism, imbalance of intestinal flora, poor patient compliance and great side effects, so that a generally accepted treatment scheme does not exist at present. How to reduce the Hp infection rate and reduce the side effect of the medicine is still a problem which needs to be solved urgently in clinic.
Disclosure of Invention
Aiming at the technical problems of the existing Hp infection, the invention provides a traditional Chinese medicine extract with a function of treating Hp-related gastritis and a preparation method and application thereof.
In order to achieve the purpose of the invention, the embodiment of the invention adopts the following technical scheme:
the traditional Chinese medicine extract is prepared by decocting traditional Chinese medicine raw materials with water, wherein the traditional Chinese medicine raw materials comprise the following components in parts by mass: 5-14 parts of basil; 2-5 parts of fructus evodiae; 5-14 parts of zanthoxylum seeds; 5-14 parts of black nightshade; 8-16 parts of mock strawberry; 8-16 parts of agastache rugosus; 8-16 parts of eupatorium; 8-16 parts of fructus amomi; 15-25 parts of oriental wormwood; 8-16 parts of immature bitter orange; 8-16 parts of mangnolia officinalis and 2-12 parts of honey-fried licorice root.
Further, the traditional Chinese medicine extract with the function of treating the Hp-related gastritis comprises the following components in parts by mass: 7-12 parts of basil; 2-4 parts of fructus evodiae; 7-12 parts of zanthoxylum seeds; 7-12 parts of black nightshade; 10-14 parts of mock strawberry; 10-14 parts of agastache rugosus; 10-14 parts of eupatorium; 10-14 parts of fructus amomi; 18-22 parts of oriental wormwood; 10-14 parts of immature bitter orange; 10-14 parts of mangnolia officinalis and 4-8 parts of honey-fried licorice root.
Further, the traditional Chinese medicine extract with the function of treating the Hp-related gastritis comprises the following components in parts by mass: 9 parts of basil; 3 parts of fructus evodiae; 9 parts of zanthoxylum seeds; 9 parts of black nightshade; 12 parts of Indian mockstrawberry herb; 12 parts of wrinkled gianthyssop herb; 12 parts of eupatorium; 12 parts of fructus amomi; 20 parts of oriental wormwood; 12 parts of immature bitter orange; 12 parts of magnolia officinalis and 6 parts of honey-fried licorice root.
In the present invention, basil: pungent and sweet in flavor and warm in nature; it enters lung, spleen, stomach and large intestine meridians; dispelling wind, relieving exterior syndrome, eliminating dampness, regulating the middle warmer, promoting qi and blood circulation, removing toxic substance, and relieving swelling; can be used for treating dyspepsia, anorexia, abdominal distention, pain, emesis, dysentery, and digestive tract ulcer.
Evodia fruit: pungent, bitter and hot in flavor; entering liver, spleen, stomach and kidney meridians; dispel cold and alleviate pain, check adverse rise of qi and arrest vomiting, strengthen yang and check diarrhea; can be used for treating gastralgia, vomiting and diarrhea due to cold of viscera, and syndrome of deficiency-cold of liver and stomach and adverse rising of yin-turbid.
Pepper seeds: bitter taste and cold nature; entering lung, kidney and bladder meridians; induce diuresis to alleviate edema, dispel phlegm and relieve asthma; can be used for anti-inflammatory and anti-tumor.
Black nightshade: bitter taste and cold nature; it enters kidney and spleen meridians. Clearing away heat and toxic materials, promoting blood circulation, and relieving swelling; it can be used for treating furuncle, carbuncle, swelling, and erysipelas.
The Indian strawberry: sweet, bitter and cold in nature; entering lung, liver and large intestine meridians; clearing away heat and toxic materials, removing blood stasis, relieving swelling, cooling blood, and stopping bleeding; the modern pharmacological research has the effects of resisting tumor and enhancing immunity.
Agastache rugosus: pungent taste and mild nature; spleen, stomach and lung meridians entered; fragrant, resolving dampness, regulating the middle warmer, relieving vomiting, relieving exterior syndrome and relieving summer-heat; is suitable for summer-heat and dampness stagnation, abdominal distention and fullness, and has spasmolytic, antiseptic, and antibacterial effects.
Herba Eupatorii: pungent taste and mild nature; spleen, stomach and lung meridians entered; fragrant, resolving dampness, activating spleen, stimulating appetite, relieving exterior syndrome and relieving summer-heat; can be used for treating damp retention in middle energizer, abdominal distention, vomiting, summer-heat dampness, and damp-warm disease.
Amomum fruit: pungent taste and warm nature; resolving dampness, promoting appetite, warming spleen and relieving diarrhea; can be used for treating abdominal distention, diarrhea, emesis, anorexia, and loose stool; and has the functions of strengthening stomach, helping digestion and eliminating flatulence symptoms.
Herba artemisiae scopariae: bitter, pungent and slightly cold in nature; spleen, stomach, liver and gallbladder meridians entered; clearing away damp-heat, promoting bile flow and eliminating jaundice; can be used for treating diseases such as summer-heat dampness, damp-warm disease, incoordination between liver and stomach, etc., and has antitumor, antipyretic, and hepatoprotective effects.
Immature bitter orange: bitter, pungent and sour in flavor, slightly cold in nature; spleen and stomach meridians entered; break qi, remove food retention, resolve phlegm and remove abdominal mass; has effects in treating gastrointestinal stagnation, damp-heat dysentery; regulating gastrointestinal motility, resisting ulcer, and inhibiting bacteria.
Magnolia officinalis: bitter and pungent taste, slightly warm in nature; the spleen, stomach, lung and large intestine meridians entered; eliminating dampness and phlegm, descending qi and eliminating fullness; for damp stagnation in the middle energizer, abdominal mass, vomiting and diarrhea, food stagnation, qi stagnation, abdominal distention, constipation, phlegm retention, asthma and cough; has antibacterial and gastric ulcer preventing effects.
Honey-fried licorice root: sweet in flavor, neutral in nature, entering stomach, heart, lung and spleen meridians; invigorating spleen and replenishing qi, eliminating phlegm and relieving cough, relieving spasm and pain, and harmonizing drug property; has the effects of treating weakness of the spleen and the stomach, harmonizing the effect of the medicines, resisting helicobacter pylori and resisting ulcer.
Compared with the prior art, the traditional Chinese medicine extract with the function of treating the Hp-related gastritis provided by the invention has the advantages that in 12 medicines, monarch, minister, assistant and guide supplement each other, wherein basil, evodia rutaecarpa and zanthoxylum seeds are pungent in flavor, warm in nature and can block, and cold dispelling and pain relieving are monarch; the black nightshade, the Indian mockstrawberry herb, the wrinkled giant hyssop herb and the fortune eupatorium herb are used as ministers with the functions of eliminating turbid pathogen with aromatics and clearing away heat and toxic materials; fructus Amomi, herba Artemisiae Scopariae, fructus Aurantii Immaturus, cortex Magnolia officinalis, and has effects in eliminating turbid pathogen with aromatics, activating spleen, and promoting qi circulation; the prepared licorice root, in combination with the other drugs, has the effects of warming yang, resolving turbidity and detoxifying. The invention aims to treat both principal and secondary aspects of disease, adopts the traditional Chinese medicine extract to be matched with the tetragenous bactericide, and regulates and controls the network through the inflammatory factors so as to achieve the aims of reducing the disease rate of Hp and reducing the side effect of the bactericide.
The invention also provides a preparation method of the traditional Chinese medicine extract for treating the Hp-related gastritis. The preparation method comprises the following steps: soaking herba Ocimi, fructus evodiae, semen Zanthoxyli, herba Solani Nigri, herba Duchesneae Indicae, herba Agastaches, herba Eupatorii, fructus Amomi, herba Artemisiae Scopariae, fructus Aurantii Immaturus, cortex Magnolia officinalis and radix Glycyrrhizae Preparata in water, heating, decocting, and filtering to obtain extractive solution.
The preparation method of the traditional Chinese medicine extract with the function of treating the Hp-related gastritis, which is provided by the invention, has the advantages of simple process, convenience in operation, safety and environmental friendliness, and can furthest retain active ingredients in the traditional Chinese medicine and ensure the efficacy of the medicine.
Furthermore, the soaking temperature is 15-25 ℃, the soaking time is 30-60 min, so that water is fully contacted with the traditional Chinese medicine, good soaking and permeating effects are achieved, the subsequent decoction and extraction are facilitated, and meanwhile, the decomposition of the effective components of the traditional Chinese medicine caused by long-time soaking is avoided.
Furthermore, the decoction temperature is 80-100 ℃, the time is 30-40 min, the active ingredients of the traditional Chinese medicine are not damaged, and the extraction rate is improved.
Furthermore, the water dosage is 6-8 times of the total mass of the traditional Chinese medicine, so that the leaching effect is ensured.
The invention also provides a traditional Chinese medicine preparation with the function of treating the Hp-related gastritis, which contains the traditional Chinese medicine extract with the function of treating the Hp-related gastritis.
The traditional Chinese medicine preparation with the function of treating Hp-related gastritis contains the traditional Chinese medicine extract, all medicines are combined, monarch, minister, assistant and guide supplement each other, the whole formula has the effects of warming yang, eliminating turbidity and detoxifying, and the four-combined bactericidal drug is matched, so that the traditional Chinese medicine preparation is safe and reliable, has no toxic or side effect, can effectively improve the eradication rate of helicobacter pylori, can reduce the side effect of the bactericidal drug, and promotes the repair of gastric mucosa.
Further, the traditional Chinese medicine preparation also comprises pharmaceutically acceptable auxiliary materials, wherein the auxiliary materials are selected from excipient, lubricant, disintegrant, filler and adhesive.
Furthermore, the dosage form of the traditional Chinese medicine preparation is oral liquid, capsules, tablets, granules or pills.
The invention also provides application of the traditional Chinese medicine extract with the function of treating the Hp-related gastritis in preparing a medicine with the function of treating the Hp-related gastritis.
The traditional Chinese medicine extract with the function of treating the Hp-related gastritis is prepared into different traditional Chinese medicine preparations by a conventional method.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
In order to better illustrate the traditional Chinese medicine extract for treating Hp-related gastritis provided by the embodiments of the present invention, the following examples further illustrate the extract.
Example 1
The traditional Chinese medicine extract is prepared by decocting traditional Chinese medicine raw materials with water, wherein the traditional Chinese medicine raw materials comprise the following components in parts by mass: 5g of basil; 5g of fructus evodiae; 5g of zanthoxylum bungeanum maxim; 5g of black nightshade; 8g of mock strawberry; 8g of wrinkled gianthyssop herb; 8g of eupatorium fortunei; 8g of fructus amomi; 25g of oriental wormwood; 16g of immature bitter orange; 16g of magnolia officinalis and 2g of honey-fried licorice root.
The preparation method of the traditional Chinese medicine extract specifically comprises the following steps:
adding the basil, the evodia rutaecarpa, the pricklyash peel, the black nightshade, the Indian mockstrawberry herb, the wrinkled gianthyssop herb, the fortune eupatorium herb, the villous amomum fruit, the virgate wormwood herb, the immature bitter orange, the officinal magnolia bark and the honey-fried licorice root into water which is 6 times of the total mass of the traditional Chinese medicines, soaking for 40min at 25 ℃, heating to 100 ℃, decocting for 30min, and filtering.
The traditional Chinese medicine extract with the function of treating the Hp-related gastritis is prepared into traditional Chinese medicine oral liquid by adopting a conventional method.
Example 2
The traditional Chinese medicine extract is prepared by decocting traditional Chinese medicine raw materials with water, wherein the traditional Chinese medicine raw materials comprise the following components in parts by mass: 14g of basil; 2g of fructus evodiae; 14g of zanthoxylum bungeanum maxim; 14g of black nightshade; 16g of Indian mockstrawberry herb; 16g of wrinkled gianthyssop herb; 16g of eupatorium fortunei; 16g of fructus amomi; 15g of oriental wormwood; 8g of immature bitter orange; 8g of magnolia officinalis and 12g of honey-fried licorice root.
The preparation method of the traditional Chinese medicine extract specifically comprises the following steps:
adding the basil, the evodia rutaecarpa, the pricklyash peel, the black nightshade, the Indian mockstrawberry herb, the wrinkled gianthyssop herb, the fortune eupatorium herb, the villous amomum fruit, the virgate wormwood herb, the immature bitter orange, the officinal magnolia bark and the honey-fried licorice root into water which is 8 times of the total mass of the traditional Chinese medicines, soaking for 60min at 15 ℃, heating to 80 ℃, decocting for 40min, and filtering.
The traditional Chinese medicine extract with the function of treating Hp-related gastritis is prepared into traditional Chinese medicine tablets by adopting a conventional method.
Example 3
The traditional Chinese medicine extract is prepared by decocting traditional Chinese medicine raw materials with water, wherein the traditional Chinese medicine raw materials comprise the following components in parts by mass: 7g of basil; 2g of fructus evodiae; 7g of zanthoxylum bungeanum maxim; 7g of black nightshade; 10g of mock strawberry; 10g of wrinkled gianthyssop herb; 10g of eupatorium fortunei; 10g of fructus amomi; 18g of oriental wormwood; 10g of immature bitter orange; 10g of magnolia officinalis and 4g of honey-fried licorice root.
The preparation method of the traditional Chinese medicine extract specifically comprises the following steps:
adding the basil, the evodia rutaecarpa, the pricklyash peel, the black nightshade, the Indian mockstrawberry herb, the wrinkled gianthyssop herb, the fortune eupatorium herb, the villous amomum fruit, the virgate wormwood herb, the immature bitter orange, the officinal magnolia bark and the honey-fried licorice root into water 7 times of the total mass of the traditional Chinese medicines, soaking for 30min at 20 ℃, heating to 90 ℃, decocting for 35min, and filtering to obtain.
The traditional Chinese medicine extract with the function of treating the Hp-related gastritis is prepared into traditional Chinese medicine oral liquid by adopting a conventional method.
Example 4
The traditional Chinese medicine extract is prepared by decocting traditional Chinese medicine raw materials with water, wherein the traditional Chinese medicine raw materials comprise the following components in parts by mass: 12g of basil; 4g of fructus evodiae; 12g of zanthoxylum bungeanum maxim; 12g of black nightshade; 14g of Indian mockstrawberry herb; 14g of wrinkled gianthyssop herb; 14g of eupatorium fortunei; 14g of fructus amomi; 22g of oriental wormwood; 14g of immature bitter orange; 14g of magnolia officinalis and 8g of honey-fried licorice root.
The preparation method of the traditional Chinese medicine extract specifically comprises the following steps:
adding the basil, the evodia rutaecarpa, the pricklyash peel, the black nightshade, the Indian mockstrawberry herb, the wrinkled gianthyssop herb, the fortune eupatorium herb, the villous amomum fruit, the virgate wormwood herb, the immature bitter orange, the officinal magnolia bark and the honey-fried licorice root into water which is 6 times of the total mass of the traditional Chinese medicines, soaking the mixture for 40min at 20 ℃, heating the mixture to 80 ℃, decocting the mixture.
The traditional Chinese medicine extract with the function of treating the Hp-related gastritis is prepared into traditional Chinese medicine granules by adopting a conventional method.
Example 5
The traditional Chinese medicine extract is prepared by decocting traditional Chinese medicine raw materials with water, wherein the traditional Chinese medicine raw materials comprise the following components in parts by mass: 9g of basil; 3g of fructus evodiae; 9g of zanthoxylum bungeanum maxim; 9g of black nightshade; 12g of Indian mockstrawberry herb; 12g of wrinkled gianthyssop herb; 12g of eupatorium fortunei; 12g of fructus amomi; 20g of oriental wormwood; 12g of immature bitter orange; 12g of magnolia officinalis and 6g of honey-fried licorice root.
The preparation method of the traditional Chinese medicine extract specifically comprises the following steps:
adding the basil, the evodia rutaecarpa, the pricklyash peel, the black nightshade, the Indian mockstrawberry herb, the wrinkled gianthyssop herb, the fortune eupatorium herb, the villous amomum fruit, the virgate wormwood herb, the immature bitter orange, the officinal magnolia bark and the honey-fried licorice root into water which is 6 times of the total mass of the traditional Chinese medicines, soaking for 40min at 25 ℃, heating to 90 ℃, decocting for 30min, and filtering.
The traditional Chinese medicine extract with the function of treating the Hp-related gastritis is prepared into traditional Chinese medicine oral liquid by adopting a conventional method.
Comparative example 1
A traditional Chinese medicine extract with a function of treating Hp-related gastritis is prepared by decocting traditional Chinese medicine raw materials with water, wherein on the basis of example 1, zanthoxylum seeds are replaced by equal amount of tuckahoe, Indian mockstrawberry is replaced by equal amount of andrographis paniculata, other components are the same as example 1, and the traditional Chinese medicine raw materials comprise the following components in parts by mass: 5g of basil; 5g of fructus evodiae; 5g of poria cocos; 5g of black nightshade; 8g of common andrographis herb; 8g of wrinkled gianthyssop herb; 8g of eupatorium fortunei; 8g of fructus amomi; 25g of oriental wormwood; 16g of immature bitter orange; 16g of magnolia officinalis and 2g of honey-fried licorice root.
The preparation method of the traditional Chinese medicine extract specifically comprises the following steps:
adding the above herba Ocimi, fructus evodiae, Poria, herba Solani Nigri, herba Andrographitis, herba Agastaches, herba Eupatorii, fructus Amomi, herba Artemisiae Scopariae, fructus Aurantii Immaturus, cortex Magnolia officinalis and radix Glycyrrhizae Preparata into 6 times of water, soaking at 25 deg.C for 40min, heating to 100 deg.C, decocting for 30min, and filtering to obtain extractive solution.
The traditional Chinese medicine extract with the function of treating the Hp-related gastritis is prepared into traditional Chinese medicine oral liquid by adopting a conventional method.
In order to better illustrate the characteristics of the traditional Chinese medicine extract for treating Hp-related gastritis provided by the embodiment of the invention, the traditional Chinese medicine extracts prepared in example 1 and comparative example 1 are tested for prevention and treatment effects.
The present invention is described in further detail below in connection with clinical trials and typical cases.
First, clinical test
1. Clinical data:
1.1 general data
180 patients with outpatient and hospitalized Hp-related gastritis were selected and divided into 3 groups by the eRankine method, i.e., 60 patients in each of the example-treated group, the comparative example-treated group and the control group. Among these, 38 men and 22 women were treated. Mean (40.75 ± 11.71 years), 35 men and 25 women in the control treatment group. Mean (41.65. + -. 11.62 years), 36 men and 14 women in the control group. Mean (39.83 ± 11.55 years old). The general data comparison is not statistically significant (P >0.05), and the difference is comparable.
1.2 diagnostic criteria
The Western medicine diagnosis standard refers to the Chinese Chronic gastritis consensus opinion (2017, Shanghai), the Chinese and Western medicine combination diagnosis and treatment consensus opinion for chronic non-atrophic gastritis (2017), the Chinese and Western medicine combination diagnosis and treatment consensus opinion for chronic atrophic gastritis (2017), and the Chinese medicine diagnosis standard refers to the Chinese medicine new drug clinical guidance research principle.
The method specifically comprises the following steps: (1) clinical symptoms: fullness or pain in the stomach, nausea, vomiting, poor appetite, eructation, acid regurgitation, dry mouth, bitter taste; (2) and passed through laboratory 14CPositive in breath test; (3) gastroscope, pathological diagnosis are CAG (with intestinal or intraepithelial neoplasia) or CSG (with erosion or bile reflux).
1.3 inclusion criteria
The gastroscope diagnoses chronic gastritis and has clinical symptoms; ② 20-70 years old; ③ Hp positive patients; (iv) receiving the treatment for eradication of Hp for the first time; signing an informed consent.
1.4 exclusion criteria
Antibiotic, bismuth agent and PPI are used in the first two weeks of treatment; second, the patient has the operation history of the digestive tract; ③ pregnant and lactating women; fourthly, people with allergic constitution or people allergic to various medicines; fifthly, patients with serious primary diseases and mental diseases such as liver, kidney and hematopoietic system are combined.
2. The treatment method comprises the following steps:
examples the treatment group, the comparative treatment group and the control group were all given tetrad bactericidal drugs: the esomeprazole magnesium enteric-coated tablet (Aslicon pharmaceutical Co., Ltd., national drug standard number H20046379, specification: 20mg multiplied by 7 tablets) is 20mg each time, 2 times per day; ornidazole dispersible tablet (Hunan Jiuzhan pharmaceutical Co., Ltd., national Standard number H20040460, specification: 0.25g × 24 tablets) 0.5g each time, 2 times/day; amoxicillin dispersible tablets (Shanxi Tongda pharmaceutical industry Co., Ltd., national drug Standard number H20000492, specification: 500mg X24 tablets) 1.0g each time, 2 times per day; bismuth potassium citrate granules (Lizhu group Lizhu pharmaceutical factory, national standard number H10900086, specification: 1.0g × 56 bags) are treated for 2 weeks 1.0g each time and 2 times per day.
2.1 treatment group of examples: administering 300 ml/dose of the traditional Chinese medicine extract obtained in the embodiment 1 of the invention, 1 dose per day, warm taking twice, and oral taking for 4 weeks; comparative example treatment group: the extract of the Chinese traditional medicine obtained in comparative example 1 was administered at 300 ml/dose, 1 dose per day, twice with warm water, and orally for 4 weeks.
2.2 control group: the placebo (200 g of rice is stir-baked and 1/20 of the amount of the raw material medicament in example 1, and the traditional Chinese medicine extract is prepared by the method in example 1) of the traditional Chinese medicine is administered for 300 ml/dose, 1 dose is taken twice warmly and orally for 4 weeks.
3. Observation indexes are as follows: clinical symptoms, Hp, gastroscopy, pathology.
3.1 clinical symptoms: fullness or pain in the stomach, nausea, vomiting, poor appetite, belching, acid regurgitation, dry mouth and bitter taste. The accumulation of symptom scores is carried out according to the severity of clinical symptoms of patients, the score of heavy, medium, light and none is respectively 3, 2, 1 and 0, and the higher the score is, the more serious the symptoms are, and vice versa. The treatment period was recorded weekly.
3.2 Hp: the patient is on an empty stomach in the early morning, and the physician guides the patient to complete the operation, and the detection is carried out by adopting a HUBT-01 Hp detector of Shenzhen Zhonghehai De Wei Biotech Co. The rate of eradication of Hp is 100% per total number of negative cases.
3.3 gastroscope: the patient had an empty stomach in the morning and was examined by a specialist using a GIF-H260 gastroscope, manufactured by Olympus, Japan. According to the consensus of Chinese Chronic gastritis (2017, Shanghai), the gastric mucosa under gastroscope is divided into 0, 1, 2 and 3 points according to the condition of absence, lightness, middle and weight of the gastric mucosa, such as erythema, roughness or edema, hemorrhage or speckle, erosion, bile reflux, blood vessel appearance, and granule or nodular shape.
3.4 pathological conditions: during operation, biopsy is carried out by collecting lesion parts by biopsy forceps, fixing is carried out by adopting 10% formalin solution, dehydrated paraffin is embedded, and HE staining is adopted. The histopathological evaluation criteria, i.e., activity, chronic inflammation, atrophy and intestinal metaplasia, were made according to the consensus on chronic gastritis (2017, Shanghai) and were counted as 0, 1, 2 and 3 points for none, light, medium and heavy points, respectively.
4. The evaluation standard of curative effect is as follows:
referring to the clinical guidance and research principles of new traditional Chinese medicines, clinical cure is as follows: the symptom and the physical sign disappear or basically disappear, the symptom score is reduced by more than or equal to 95 percent, 14 percentCThe test turns negative, and the symptom integral and the histopathology integral of the mucosa under the gastroscope are reduced by more than or equal to 95 percent; the effect is shown: the symptoms and physical signs are obviously improved, the symptom score is reduced by more than or equal to 70 percent, 14 percentCThe test turns negative, and the symptom integral and the histopathology integral of the mucosa under the gastroscope are reduced by more than or equal to 70 percent; the method has the following advantages: the symptoms and physical signs are all improved, the symptom score is reduced by more than or equal to 30 percent, 14 percentCThe test is positive, the symptom integral and the histopathology integral of mucosa under the gastroscope are reduced by more than 50 percent; and (4) invalidation: clinical symptoms and physical signs are not relieved or aggravated, the symptom integral is reduced by less than 30 percent compared with the prior one, the symptom integral of mucosa under a gastroscope and the histopathology integral are reduced by less than 50 percent, and a nimodipine method is adopted as a calculation formula of the reduction percentage of the symptom integral.
5. Before and after treatment, the blood, urine and stool routine of the patient, electrocardiogram, liver and kidney functions, gastrointestinal adverse reactions and the like are detected.
6. The statistical method comprises the following steps:
data were statistically analyzed using SPSS25.0 software. The measured data conforms to the normal distribution with mean + -standard deviation
Represents; before and after the treatment in the group, the matching t test is adopted, and the comparison between the groups is carried out if the normal condition is metIf the distribution is not consistent, selecting rank sum test; and the grade curative effect evaluation data adopts rank sum test. The difference is statistically significant when P is less than 0.05.
7. The treatment results are as follows:
7.1 Total score of chief complaints after treatment of three groups of patients (as shown in Table 1): fullness or pain in the stomach, nausea, vomiting, poor appetite, belching, acid regurgitation, dry mouth and bitter taste.
TABLE 1 Total score of chief complaints after treatment
Note: the total score of the symptoms before the two groups of treatments was not statistically significant (P)>0.05), treatment group pre-treatment comparison P<0.05, post-treatment compared to control group△P<0.05。
As can be seen from the data in Table 1, the total score of the three pre-treatment groups was not statistically significant (P)>0.05), the total integral of symptoms was significantly reduced and the difference P was significant before and after treatment in the treatment groups of examples<0.05, the total integral of symptoms of the treatment groups of the examples is obviously reduced and the difference is obvious compared with that of the control group after treatment△P<0.05, and the effect of the treatment group of the embodiment is better than that of the treatment group of the comparative example.
7.2 comparison of the clinical effects of the three groups
As shown in table 2, the treatment groups of the examples clinically cured 31 cases, the significant effect of 21 cases, the effective cases of 7 cases, and the ineffective cases of 1 case, the rate of eradication of Hp was 86.67%, and the total effective rate was 98.33%, the treatment groups of the comparative examples clinically cured 27 cases, the significant effect of 19 cases, the effective cases of 11 cases, and the ineffective cases of 3 cases, the rate of eradication of Hp was 86.67%, and the total effective rate was 98.33%, the clinical cure of the control groups was 23 cases, the significant effect of 17 cases, the effective cases of 14 cases, the ineffective cases of 6 cases, the rate of eradication of Hp was 68.33%, and the total effective rate was 90%, and the two groups had.
TABLE 2
7.3 integration of the endoscopic mucosal signs before and after treatment in three groups of patients
As shown in Table 3, the score of gastric mucosa signs before three groups of treatments is not statistically significant (P >0.05), the score of gastric mucosa signs of patients in the treatment groups of the examples after the treatment is reduced compared with that before the treatment and is superior to that of the control group, the difference is statistically significant (P <0.05), and meanwhile, the effect of the treatment groups of the examples is superior to that of the treatment groups of the comparative examples.
TABLE 3
7.4 integration of histopathological changes before and after treatment in three groups of patients
As shown in Table 4, the number of people in each period before the three groups had no statistical significance (P)>0.05), the histopathological change score is obviously reduced and the difference is obvious P compared with the treatment group of the example before and after treatment<0.05, the histopathology change score of the example treated group is obviously reduced and the difference is obvious compared with that of the control group after treatment△P<0.05, the effect of the treatment group of the example was superior to that of the treatment group of the comparative example.
TABLE 4
7.5 adverse reaction results for three groups of patients are shown in Table 5.
TABLE 5
Note: p of the treatment group is less than 0.05 compared with the control group
According to the data, the traditional Chinese medicine extract with the function of treating the Hp-related gastritis provided by the embodiment of the invention is prepared by supplementing 12 medicines, monarch, minister, assistant and guide, has the effects of warming yang, resolving turbidity and detoxifying, is safe and reliable, has no toxic or side effect, can effectively improve the eradication rate of helicobacter pylori, can reduce the side effect of a bactericidal medicine, promotes the repair of gastric mucosa, and has an obvious effect.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents or improvements made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (10)
1. The traditional Chinese medicine extract with the function of treating the Hp-related gastritis is characterized by being prepared by decocting traditional Chinese medicine raw materials in water, wherein the traditional Chinese medicine raw materials comprise the following components in parts by mass: 5-14 parts of basil; 2-5 parts of fructus evodiae; 5-14 parts of zanthoxylum seeds; 5-14 parts of black nightshade; 8-16 parts of mock strawberry; 8-16 parts of agastache rugosus; 8-16 parts of eupatorium; 8-16 parts of fructus amomi; 15-25 parts of oriental wormwood; 8-16 parts of immature bitter orange; 8-16 parts of mangnolia officinalis and 2-12 parts of honey-fried licorice root.
2. The traditional Chinese medicine extract with the function of treating Hp-related gastritis as claimed in claim 1, wherein the traditional Chinese medicine raw materials comprise the following components in parts by mass: 7-12 parts of basil; 2-4 parts of fructus evodiae; 7-12 parts of zanthoxylum seeds; 7-12 parts of black nightshade; 10-14 parts of mock strawberry; 10-14 parts of agastache rugosus; 10-14 parts of eupatorium; 10-14 parts of fructus amomi; 18-22 parts of oriental wormwood; 10-14 parts of immature bitter orange; 10-14 parts of mangnolia officinalis and 4-8 parts of honey-fried licorice root.
3. The traditional Chinese medicine extract with the function of treating Hp-related gastritis as claimed in claim 1, wherein the traditional Chinese medicine raw materials comprise the following components in parts by mass: 9 parts of basil; 3 parts of fructus evodiae; 9 parts of zanthoxylum seeds; 9 parts of black nightshade; 12 parts of Indian mockstrawberry herb; 12 parts of wrinkled gianthyssop herb; 12 parts of eupatorium; 12 parts of fructus amomi; 20 parts of oriental wormwood; 12 parts of immature bitter orange; 12 parts of magnolia officinalis and 6 parts of honey-fried licorice root.
4. The method for preparing the herbal extract for treating Hp-related gastritis according to any one of claims 1 to 3, comprising the steps of:
soaking herba Ocimi, fructus evodiae, semen Zanthoxyli, herba Solani Nigri, herba Duchesneae Indicae, herba Agastaches, herba Eupatorii, fructus Amomi, herba Artemisiae Scopariae, fructus Aurantii Immaturus, cortex Magnolia officinalis and radix Glycyrrhizae Preparata in water, heating, decocting, and filtering to obtain extractive solution.
5. The method for preparing the traditional Chinese medicine extract with the function of treating the Hp-related gastritis according to claim 4, wherein the preparation method comprises the following steps: the soaking temperature is 15-25 ℃, and the soaking time is 30-60 min.
6. The method for preparing the traditional Chinese medicine extract with the function of treating the Hp-related gastritis according to claim 4, wherein the preparation method comprises the following steps: the decoction temperature is 80-100 ℃, and the time is 30-40 min.
7. The method for preparing the traditional Chinese medicine extract with the function of treating the Hp-related gastritis according to claim 4, wherein the preparation method comprises the following steps: the water dosage is 6-8 times of the total mass of the traditional Chinese medicine.
8. A traditional Chinese medicine preparation with a function of treating Hp-related gastritis, which is characterized by comprising the traditional Chinese medicine extract with the function of treating Hp-related gastritis in any one of claims 1 to 3.
9. The traditional Chinese medicine preparation with the function of treating Hp-related gastritis according to claim 8, wherein the dosage form of the traditional Chinese medicine preparation is oral liquid, capsules, tablets, granules or pills.
10. Use of the extract of any one of claims 1 to 3 for the preparation of a medicament for the treatment of Hp-related gastritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011040023.7A CN111991535B (en) | 2020-09-28 | 2020-09-28 | Traditional Chinese medicine extract with function of treating helicobacter pylori-associated gastritis and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011040023.7A CN111991535B (en) | 2020-09-28 | 2020-09-28 | Traditional Chinese medicine extract with function of treating helicobacter pylori-associated gastritis and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111991535A true CN111991535A (en) | 2020-11-27 |
| CN111991535B CN111991535B (en) | 2021-10-26 |
Family
ID=73475418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011040023.7A Active CN111991535B (en) | 2020-09-28 | 2020-09-28 | Traditional Chinese medicine extract with function of treating helicobacter pylori-associated gastritis and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111991535B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220127466A (en) * | 2021-03-11 | 2022-09-20 | 전남대학교산학협력단 | Composition for improving, preventing or treating Helicobacter pylori infection |
| CN115554374A (en) * | 2022-10-13 | 2023-01-03 | 河北中医学院 | Traditional Chinese medicine composition for treating helicobacter pylori gastritis and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101385837A (en) * | 2008-10-16 | 2009-03-18 | 杨启泽 | Chinese prepared medicine for treating gastrosis |
| CN104645202A (en) * | 2015-01-30 | 2015-05-27 | 河北省中医院 | Traditional Chinese medicine preparation for treating chronic gastritis |
| CN108114227A (en) * | 2017-10-25 | 2018-06-05 | 马雪英 | A kind of drug for treating stomachache and preparation method thereof |
| CN109289033A (en) * | 2018-12-19 | 2019-02-01 | 吴其东 | A kind of Chinese medicine composition that treating cold-dampness stomach trouble and preparation method |
-
2020
- 2020-09-28 CN CN202011040023.7A patent/CN111991535B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101385837A (en) * | 2008-10-16 | 2009-03-18 | 杨启泽 | Chinese prepared medicine for treating gastrosis |
| CN104645202A (en) * | 2015-01-30 | 2015-05-27 | 河北省中医院 | Traditional Chinese medicine preparation for treating chronic gastritis |
| CN108114227A (en) * | 2017-10-25 | 2018-06-05 | 马雪英 | A kind of drug for treating stomachache and preparation method thereof |
| CN109289033A (en) * | 2018-12-19 | 2019-02-01 | 吴其东 | A kind of Chinese medicine composition that treating cold-dampness stomach trouble and preparation method |
Non-Patent Citations (4)
| Title |
|---|
| 易敏文等: "半夏泻心汤加减治疗慢性浅表性胃炎53例", 《湖北中医杂志》 * |
| 李翠竹: "辨证分型治疗慢性萎缩性胃炎34例疗效观察", 《中国社区医师》 * |
| 王体福: "慢性胃炎用药浅析", 《泸州医学院学报》 * |
| 让建忠: "半夏泻心汤加味治疗慢性胃炎40例", 《中国民间疗法》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220127466A (en) * | 2021-03-11 | 2022-09-20 | 전남대학교산학협력단 | Composition for improving, preventing or treating Helicobacter pylori infection |
| KR102491196B1 (en) | 2021-03-11 | 2023-01-20 | 전남대학교 산학협력단 | Composition for Improving, Preventing or Treating Helicobacter pylori Infection |
| CN115554374A (en) * | 2022-10-13 | 2023-01-03 | 河北中医学院 | Traditional Chinese medicine composition for treating helicobacter pylori gastritis and preparation method and application thereof |
| CN115554374B (en) * | 2022-10-13 | 2023-07-07 | 河北中医学院 | Traditional Chinese medicine composition for treating helicobacter pylori gastritis as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111991535B (en) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111671880B (en) | Traditional Chinese medicine preparation for treating fever caused by coronavirus pneumonia | |
| CN111991535B (en) | Traditional Chinese medicine extract with function of treating helicobacter pylori-associated gastritis and preparation method and application thereof | |
| CN101439164A (en) | Preparation method of traditional Chinese medicine for treating excessive-fire type aphtha | |
| CN113713057B (en) | Traditional Chinese medicine composition and application thereof | |
| CN113209238A (en) | Lotion for treating hand-foot syndrome caused by targeted medicament and preparation method thereof | |
| CN104083747B (en) | A kind of pharmaceutical composition for treating chronic gastritis and preparation method and purposes | |
| CN113768978B (en) | Yi medicine composition for treating ulcerative colitis and preparation method thereof | |
| CN105833115B (en) | Traditional Chinese medicine for treating gastric precancerous lesion | |
| CN110856741A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating diarrhea | |
| CN104225016B (en) | A kind of pharmaceutical composition treating due to weakness of spleen and stomach chronic atrophic gastritis | |
| CN101693084A (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN105395975A (en) | Enema traditional Chinese medicine composition treating ulcerative colitis and preparation method thereof | |
| CN105412822A (en) | Spleen-strengthening blood stasis-removing Chinese herbal compound composition and application thereof | |
| CN111494583A (en) | A pharmaceutical composition for treating chronic atrophic gastritis and preparation method thereof | |
| CN115554374B (en) | Traditional Chinese medicine composition for treating helicobacter pylori gastritis as well as preparation method and application thereof | |
| CN116966249B (en) | Traditional Chinese medicine composition for treating ulcerative colitis | |
| CN113633748B (en) | Medicine for treating spontaneous bacterial peritonitis damp-heat stasis syndrome of liver cirrhosis and preparation method thereof | |
| CN104208474B (en) | Traditional Chinese medicine composition for treating acute urinary tract infection and application thereof | |
| CN116159110B (en) | New use of compound traditional Chinese medicine for resolving dampness and clearing spots in treating Behcet disease | |
| CN116920057B (en) | Traditional Chinese medicine composition for treating acute and chronic gastritis and application thereof | |
| CN113769002B (en) | Traditional Chinese medicine decoction for treating gastritis verrucosa | |
| CN102697990A (en) | Traditional Chinese medicine composition used for treating perianorecrtal abscess | |
| CN102688306B (en) | Ointment for treating acute pancreatitis | |
| CN106266437A (en) | A kind of Integrated TCM preparation treating bacillary dysentery and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |